Want to see AU:ONE full AI Analyst Report?
Top Page
Oneview Healthcare Chess Depository Interests repr 1
(Sydney:ONE)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.17
▼(-1.18% Downside)
Action:Reiterated
Date:03/21/26
The score is held back primarily by weak financial performance (ongoing large losses and cash burn) and bearish technical trend (below key moving averages with negative MACD). This is partially offset by constructive earnings-call commentary pointing to sustained growth, cost reductions, and expanding commercial access (Baxter/GPO), while valuation support is limited due to loss-making results and no dividend.
Positive Factors
Revenue growth momentum
Sustained double‑digit top‑line growth and ARR expansion (7% ARR growth) indicate expanding adoption of Oneview’s platform across hospitals. Strong deployment momentum and endpoint growth targets (~20% to ~18k) support durable recurring revenue expansion versus episodic wins.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow means the business consumes cash to grow. This raises reliance on external financing, constrains runway for product investment and deployments, and makes multi‑period execution sensitive to capital markets and timing of large enterprise conversions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth momentum
Sustained double‑digit top‑line growth and ARR expansion (7% ARR growth) indicate expanding adoption of Oneview’s platform across hospitals. Strong deployment momentum and endpoint growth targets (~20% to ~18k) support durable recurring revenue expansion versus episodic wins.
Read all positive factors
Oneview Healthcare Chess Depository Interests repr 1 (ONE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$130.43M
Dividend YieldN/A
Average Volume (3M)344.03K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth29.37%
EPS Growth-10.38%
CountryAU
Employees96
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding839,193,050
10 Day Avg. Volume303,620
30 Day Avg. Volume344,030
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)47.09
Price to Sales (P/S)14.39
P/FCF Ratio-20.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside147.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$14.80M
Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model
Company Description
Oneview Healthcare PLC provides specialized software solutions and expert consulting services to the healthcare industry. Its market reach extends across Ireland, the United States, Australia, Asia, and the Middle East. The company's core offering...
How the Company Makes Money
Oneview Healthcare’s revenue model is based on selling and supporting enterprise software solutions to hospitals and healthcare systems. The primary way the company makes money is through contracts for its patient engagement and clinical workflow ...
Oneview Healthcare Chess Depository Interests repr 1 Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call communicates strong commercial momentum and meaningful progress on product innovation and AI‑driven productivity—highlighted by 21% reported revenue growth (25%+ constant currency), accelerated deployments, a major Baxter partnership and clear cost‑efficiency gains (H2 OpEx down and >EUR 1.4m annualized run‑rate savings). However, material challenges remain: the company is still operating at an EBITDA loss (EUR 8.1m), cash is modest (EUR 4.6m), gross margin was compressed by revenue mix and conversion of a large Baxter/GPO pipeline and enterprise expansions are uncertain and subject to lengthy sales cycles and regulatory/capital‑spending risks. On balance, the positives (growth, partnerships, product/AI progress and OpEx improvement) outweigh the negatives, but execution and pipeline conversion will be critical to sustain the trajectory.Positive Updates
Strong Revenue Growth
Revenues increased 21% year‑on‑year in 2025 versus 2024 (driven by a EUR 1.6m increase in non‑recurring revenue and 7% growth in annual recurring revenue). On a constant currency basis growth exceeded 25%.
Negative Updates
Ongoing Operating Loss and Cash Position
Operating EBITDA loss reduced by 8% to EUR 8.1m in 2025, but the company remains loss‑making. Cash on hand at 31 Dec 2025 was EUR 4.6m, with cash decline broadly aligned to operating EBITDA loss.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenues increased 21% year‑on‑year in 2025 versus 2024 (driven by a EUR 1.6m increase in non‑recurring revenue and 7% growth in annual recurring revenue). On a constant currency basis growth exceeded 25%.
Read all positive updates
Company Guidance
The company guided to continued revenue momentum and cost efficiency in 2026, targeting a ~20% increase in endpoints to just under 18,000 (from 14,880 at 31‑Dec‑2025), with H2 deployment activity having accelerated 31% vs H1 and recent contracts averaging ~2.5 endpoints/room; FY‑25 revenues rose 21% (constant currency >25%) driven by a €1.6m increase in non‑recurring revenue and 7% ARR growth, while operating EBITDA loss narrowed 8% to €8.1m, cash at year‑end was €4.6m and inventory €2.9m. Management expects gross margin to remain in the mid‑to‑low 60s (FY‑25: 64%, down 3ppt from mix), and OpEx savings delivered in H2‑25 (run‑rate H1‑25 ≈ €8.4m vs H2 ≈ €7.63m, >€700k half‑year saving, >€1.4m annualized) will be carried into 2026 with further reductions expected later in the year. They reiterated product and commercial levers to drive upside — 18 new logos over the last 3 years representing 11,631 licensed beds and a 46,000‑endpoint addressable set across those logos (~€16m average recurring revenue opportunity), a ~€1.50/day revenue per endpoint benchmark, a 92% upsell rate per bed, inclusion in a Baxter GPO (one of the top 10 U.S. systems) with 156+ qualified Baxter opportunities, and AI/SDLC targets (engineer time savings >15% daily for 76% of the team and a 2026 maturity target of 4/5 for key SDLC phases) supporting faster product delivery and deployments.Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.93M | 9.89M | 9.40M | 8.92M | 9.73M |
| Gross Profit | 7.12M | 6.67M | 6.16M | 5.35M | 5.31M |
| EBITDA | -10.48M | -11.26M | -7.88M | -12.09M | -8.01M |
| Net Income | -12.51M | -10.84M | -8.93M | -10.87M | -8.19M |
Balance Sheet | |||||
| Total Assets | 15.49M | 25.96M | 21.92M | 12.75M | 21.09M |
| Cash, Cash Equivalents and Short-Term Investments | 4.60M | 13.83M | 11.55M | 6.41M | 15.18M |
| Total Debt | 1.11M | 1.15M | 935.32K | 543.01K | 1.20M |
| Total Liabilities | 11.84M | 12.71M | 12.78M | 10.50M | 11.19M |
| Stockholders Equity | 3.65M | 13.25M | 9.14M | 2.26M | 9.90M |
Cash Flow | |||||
| Free Cash Flow | -8.38M | -10.52M | -7.79M | -10.24M | -4.09M |
| Operating Cash Flow | -8.32M | -10.47M | -7.26M | -10.20M | -4.03M |
| Investing Cash Flow | -116.31K | -459.78K | -521.38K | -44.52K | -65.26K |
| Financing Cash Flow | -294.26K | 13.14M | 13.04M | -100.11K | 12.22M |
Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis
Positive
0.17
Price Trends
0.16
Positive
0.17
Negative
0.23
Negative
Market Momentum
<0.01
Negative
55.02
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.16, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ONE.
Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$118.23M | 30.34 | 4.37% | ― | 36.43% | ― | |
55 Neutral | AU$69.33M | -6.92 | -23.86% | ― | -11.45% | -97.22% | |
52 Neutral | AU$40.33M | 17.89 | 250.55% | ― | 1.99% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$39.24M | -6.75 | -14.19% | ― | 0.03% | -5.85% | |
48 Neutral | AU$130.43M | -6.39 | -226.75% | ― | 29.37% | -10.38% | |
40 Underperform | AU$11.48M | -0.20 | -1566.68% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.17
-0.08
-31.84%
AU:M7T
Mach7 Technologies
0.30
-0.07
-19.18%
AU:BMT
Beamtree Holdings Ltd
0.13
-0.14
-51.92%
AU:AHE
MedAdvisor Limited
0.02
-0.05
-73.85%
AU:ALC
Alcidion Group Limited
0.09
>-0.01
-9.00%
AU:DOC
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
0.11
-0.04
-25.00%
Oneview Healthcare Chess Depository Interests repr 1 Corporate Events
Oneview maps out three-year AI strategy for bedside care orchestration
Jul 8, 2026
Oneview Healthcare is positioning itself as a key player in digital connected care, building tools that sit at the bedside to link patients, clinicians and hospital systems. Its solutions aim to streamline workflow integration in healthcare enviro...
Oneview Healthcare Cancels 16,668 Lapsed Restricted Share Units
Jun 25, 2026
Oneview Healthcare plc has reported the cessation of 16,668 restricted share units listed on the ASX under the code ONEAF, following the lapse of conditional rights that could not be satisfied. The lapse marginally reduces the company’s pote...
Oneview Healthcare Issues 200,000 Restricted Share Units Under Employee Incentive Plan
Jun 25, 2026
Oneview Healthcare plc has notified the market of the issuance of 200,000 restricted share units under its employee incentive scheme, with the securities remaining unquoted on the ASX until transfer restrictions expire. The move underscores the co...
Oneview Healthcare Adds 208,337 CDI Securities to ASX Free Float
Jun 3, 2026
Oneview Healthcare plc has applied for the quotation of 208,337 new CHESS Depositary Interests on the Australian Securities Exchange, representing ordinary shares on a 1:1 basis. These securities were previously issued under an employee incentive ...
Oneview Healthcare Reports Lapse of 935,950 Restricted Share Units
May 29, 2026
Oneview Healthcare has announced the cessation of 935,950 restricted share units after the conditions attached to these securities were not met or became incapable of being satisfied as of May 29, 2026. The lapse of these conditional rights reduce...
Oneview Healthcare Adds New ASX-Authorised Representative to Bolster Governance
May 25, 2026
Oneview Healthcare has appointed Claire Stitz, Senior Manager at Computershare Governance Services, as an additional authorised person to liaise with the ASX on Listing Rule matters and to release market announcements on the company’s behalf...
Oneview corrects director interest notice for James Fitter
May 22, 2026
Oneview Healthcare PLC has corrected an error in a previously lodged Director’s Interest Notice for director James Fitter, clarifying the accurate number of CHESS Depositary Interests held following the vesting of Restricted Share Units. The...
Oneview Healthcare Options Lapse, Trimming Potential Future Equity Issuance
May 12, 2026
Oneview Healthcare plc has announced the cessation of 577,250 options (ASX code ONEAE), which lapsed after the conditions attached to these rights were not satisfied or became incapable of being met by 9 May 2026. The lapse reduces the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.